Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oregovomab, Nivolumab, and Chemotherapy in Recurrent Ovarian Cancer
NCT04620954Phase 2Unknown
- Sponsor
- National Cancer Centre Singapore
- Start
- Oct 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oregovomab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by National Cancer Centre Singapore. Primary endpoints: Number of incidences of adverse events up to 2 years and Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
oregovomab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04620954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620954.